GlassScriptPhysician profile
Evan Grovenstein
NPI 1174184030
$3,047.47
in general payments reported to CMS, 2019-2025
29 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $308 · 2023: $543 · 2024: $691 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.06 | 2021-2025 | |
| Corcept Therapeutics | $295.89 | 2023-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.67 | 2024-2025 | Caplyta |
| Gilead Sciences, INC. | $191.41 | 2023-2024 | |
| Alkermes, INC. | $167.66 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $166.95 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $139.24 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $137.30 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $131.28 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $120.13 | 2022-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Otsuka America Pharmaceutical, INC. | $104.62 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $99.60 | 2025 | Austedo Xr, Uzedy |
| Sanofi Pasteur INC. | $57.16 | 2021-2025 | |
| Lilly USA, LLC | $55.85 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $54.81 | 2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $50.31 | 2023-2024 | Nexplanon |
| Novo Nordisk INC | $39.23 | 2024 | Rybelsus, Ozempic |
| Corium, LLC | $38.12 | 2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2022-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $30.05 | 2021-2025 | Trintellix |
| Edwards Lifesciences Corporation | $28.81 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vertex Pharmaceuticals Incorporated | $28.26 | 2025 | |
| Medtronic, INC. | $28.23 | 2024 | Minimed 780g |
| Braeburn INC. | $26.14 | 2025 | Brixadi |
| Merck Sharp & Dohme LLC | $24.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.12 | 2025 | Spravato |
| Indivior INC. | $18.33 | 2025 | Sublocade |
| Insulet Corporation | $16.52 | 2023 | Omnipod |
| Amgen INC. | $16.52 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Grovenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.